ovarian cancer

Biotech

VBL lays off 35% of staff after failure-induced stock shock

VBL Therapeutics is trimming its workforce by 35% less than two weeks after its lead asset flunked a phase 3 test.
Max Bayer Aug 2, 2022 11:03am

Panic infects VBL investors as therapy fails phase 3 cancer test

Jul 20, 2022 6:30am

Roche pays Repare $125M to join Big Pharma peers in cancer race

Jun 2, 2022 8:27am

Investors fork out $76M for piece of Pheast's cancer therapies

Apr 26, 2022 11:00am

ImmunoGen files ovarian cancer drug with FDA after iffy results

Mar 29, 2022 10:30am

Verastem takes on debt to get RAS tumor program to finish line

Mar 28, 2022 8:30am